Lacosamide vs Zonisamide (Zonegran)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Epilepsy
Shared mechanism: Voltage-gated sodium channels · full Epilepsy pipeline
Lacosamide · Vimpat
Marketed by UCB
NCT00136019 · Phase 3 · completed
Multicentre, double-blind, placebo-controlled trial (SP754): 405 patients randomised 1:2:1 to placebo, lacosamide 400 mg or 600 mg/day; the prespecified primary outcome was met. The registry record omits the arms; the design is from the publication.
The old registry record lists only the lacosamide intervention; the design and arms are from the publication.
Reported efficacy
Efficacy is evaluated based on reduction in seizure frequency, 50 percent reduction in seizures, number and percentage of seizure-free days, and achievement of seizure-free status.: Median % reduction in seizure frequency/28 days: lacosamide 400mg/day -37.3% (p=0.008), 600mg/day -37.8% (p=0.006), vs placebo -20.8%; >=50% responder rates 38.3% (400mg) and 41.2% (600mg) vs 18.3% placebo (p<0.001). (met)
Result source: NCT00136019
Zonisamide (Zonegran)
Marketed by Advanz Pharma and partners
NCT00056576 · Phase 3 · completed
Although 165 participants were reportedly randomized and treatment was double-blinded, the study is listed as a single-group design with no placebo or active comparator. No primary endpoint or results are posted, so whether the primary outcome was met or missed cannot be assessed.
Reported efficacy
Percentage of Participants Remaining in the Study at Each Visit (At 3, 6, 9, 12, 15, 18, 21, 24, and 27 months): Long-term extension; the registered primary was retention in the study at each visit, with no formal test. Retention at 12 months: zonisamide 58.4% (n=137) vs carbamazepine 61.4% (n=158) (CT.gov posted results). (not_applicable)
Result source: NCT00848549
Results for Epilepsy
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Lacosamide | Zonisamide (Zonegran) |
|---|---|---|
| Seizure frequency, % change | —Not posted · NCT00136019 | -48.4% vs -26.6%−21.8 vs placeboNCT003277171 other result
|
| 50% responder rate | —Not posted · NCT00136019 | 48.6% vs 34.9%+13.7 vs placeboNCT003277171 other result
|
| Seizure freedom | —Not posted · NCT00136019 | 1.8% vs 2.8%−1 vs placeboNCT00327717 |
Seizure frequency, % change
- Lacosamide
- —Not posted · NCT00136019
- Zonisamide (Zonegran)
- -48.4% vs -26.6%−21.8 vs placeboNCT00327717
1 other result
- -32.7% vs -35.6% NCT00292461
50% responder rate
- Lacosamide
- —Not posted · NCT00136019
- Zonisamide (Zonegran)
- 48.6% vs 34.9%+13.7 vs placeboNCT00327717
1 other result
- 45.8% vs 45.8% NCT00292461
Seizure freedom
- Lacosamide
- —Not posted · NCT00136019
- Zonisamide (Zonegran)
- 1.8% vs 2.8%−1 vs placeboNCT00327717
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
6 other shared endpoints and safety
Coverage. Lacosamide: 10 of 10 rows · Zonisamide (Zonegran): 10 of 10 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Lacosamide Rows use multiple source trials | Zonisamide (Zonegran) Rows use multiple source trials |
|---|---|---|
| Partial Onset Seizure Frequency percent change · % of baseline No placebo or comparator arm | -44.47% (n=471) @ 323wka,b,c,d NCT01832038 · Phase 3 · registry result, not featured evidence 1 other source trial-24.13% (n=308) NCT00938912 · Phase 2 · registry result, not featured evidence | -16.35% (n=102) @ 16wka,b,c,d NCT01140867 · Phase 4 · registry result, not featured evidence |
| Seizure 50 responder rate · % of participants Maintenance | 49.2% (n=179) vs 19.7% (n=183) placebo @ 24wk*400 mg/daye,f,c,g NCT01710657 · Phase 3 · registry result, not featured evidence · converted to % from 88 participants as posted show 1 more dose38.5% (n=182) vs 19.7% (n=183) placebo @ 24wk*200 mg/day NCT01710657 · Phase 3 · registry result, not featured evidence · converted to % from 70 participants as posted | 50% (n=107) vs 31% (n=100) placebo @ 20wkf,c,g NCT00566254 · Phase 3 · registry result, not featured evidence |
| Seizure 50 responder rate · % of participants No placebo or comparator arm | 57.1% (n=471) @ 323wka,b,c,d NCT01832038 · Phase 3 · registry result, not featured evidence 3 other source trials50% (n=376) NCT00515619 · Phase 3 · registry result, not featured evidence 48.2% (n=307) NCT00522275 · Phase 3 · registry result, not featured evidence 51.2% (n=369) NCT00552305 · Phase 2 · registry result, not featured evidence | 61.76% (n=102) @ 16wka,b,c,d NCT01140867 · Phase 4 · registry result, not featured evidence |
| Seizure-free absolute value · months | 3.88 vs 3.75 Levetiracetam months @ 26wk*f,c,h NCT01345058 · Phase 3 · registry result, not featured evidence · combination · converted to months from 118.11 days as posted | 0.73 vs 0.7 placebo months @ 12wk*100 mgf,c,h NCT00327717 · Phase 3 · registry result, not featured evidence · converted to months from 22.31 days as posted |
| Seizure-free responder rate · % of participants No placebo or comparator arm | 7.4% (n=323)i,f,c,j NCT00938912 · Phase 2 · registry result, not featured evidence | 57.6% (n=41) @ 24wkhigh dosee,i,f,c,j NCT01127165 · Phase 4 · registry result, not featured evidence show 1 more dose63.1% (n=49) @ 24wklow dose NCT01127165 · Phase 4 · registry result, not featured evidence |
| Time to First Seizure time to event · months | 5.32 vs 3.83 Levetiracetam months*f,c,j NCT01345058 · Phase 3 · registry result, not featured evidence · combination · converted to months from 162 days as posted | 0.73 vs 0.7 placebo months*100 mgf,c,j NCT00327717 · Phase 3 · registry result, not featured evidence · converted to months from 22.31 days as posted |
| Dropout rate | 34.3%k NCT02408549 · Phase 3 · combination show 45 more results—Lacosamide (SS) Safety Follow-up P NCT02408523 · Phase 3 —Lacosamide (SS) Taper Period NCT02408523 · Phase 3 —Lacosamide (SS) Transition Period NCT02408523 · Phase 3 —Lacosamide (SS) Treatment Period NCT02408523 · Phase 3 7.1% NCT01190098 · Phase 4 · registry result, not featured evidence 16.7%First Add-on NCT00955357 · Phase 4 · registry result, not featured evidence · add on 18.3%Later Add-on NCT00955357 · Phase 4 · registry result, not featured evidence · add on 36.8%Lacosamide: >=2 to <4 Years NCT04627285 · Phase 3 · registry result, not featured evidence 13.8%Lacosamide: >=4 to <6 Years NCT04627285 · Phase 3 · registry result, not featured evidence 26.9% NCT01964560 · Phase 3 · registry result, not featured evidence — NCT02477839 · Phase 3 · registry result, not featured evidence — NCT02582866 · Phase 3 · registry result, not featured evidence — NCT01832038 · Phase 3 · registry result, not featured evidence 36.8% NCT02124564 · Phase 3 · registry result, not featured evidence 11.7% NCT01921205 · Phase 3 · registry result, not featured evidence 24.4%Lacosamide NCT01465997 · Phase 3 · registry result, not featured evidence —Lacosamide (SS) NCT01465997 · Phase 3 · registry result, not featured evidence 40.1% NCT01243177 · Phase 3 · registry result, not featured evidence 34.8% NCT00530855 · Phase 3 · registry result, not featured evidence 0% NCT02192814 · Phase 3 · registry result, not featured evidence 25% NCT01345058 · Phase 3 · registry result, not featured evidence · combination 17.8%400 mg/day NCT01710657 · Phase 3 · registry result, not featured evidence 6.6%200 mg/day NCT01710657 · Phase 3 · registry result, not featured evidence 22.5% NCT01484977 · Phase 3 · registry result, not featured evidence 39.2%400 mg/day NCT00520741 · Phase 3 · registry result, not featured evidence 34.9%300 mg/day NCT00520741 · Phase 3 · registry result, not featured evidence 57.4% NCT00515619 · Phase 3 · registry result, not featured evidence 28.9% NCT00655486 · Phase 3 · registry result, not featured evidence 55.2% NCT00522275 · Phase 3 · registry result, not featured evidence 16%400 mg NCT00655551 · Phase 3 · registry result, not featured evidence 6%300 mg NCT00655551 · Phase 3 · registry result, not featured evidence 0%200 mg NCT00655551 · Phase 3 · registry result, not featured evidence —Lacosamide Age Cohort ≥ 1 Month - NCT02710890 · Phase 2/3 · registry result, not featured evidence —Lacosamide Age Cohort ≥ 8 - < 17 Y NCT02710890 · Phase 2/3 · registry result, not featured evidence — NCT00938912 · Phase 2 · registry result, not featured evidence 10%Lacosamide 1 Month - <4 Years NCT01969851 · Phase 2 · registry result, not featured evidence 33.3%Lacosamide 12 Years - <18 Years NCT01969851 · Phase 2 · registry result, not featured evidence 12.5%Lacosamide 4 Years - <12 Years NCT01969851 · Phase 2 · registry result, not featured evidence —400mg NCT01458522 · Phase 2 · registry result, not featured evidence 40%>=1 Month to <4 Years (Safety Set) NCT00938431 · Phase 2 · registry result, not featured evidence 88.9%>=12 Years to <=17 Years (Safety S NCT00938431 · Phase 2 · registry result, not featured evidence 39.1%>=4 Years to <12 Years (Safety Set NCT00938431 · Phase 2 · registry result, not featured evidence 25.6% NCT01118962 · Phase 2 · registry result, not featured evidence 18.4% NCT01118949 · Phase 2 · registry result, not featured evidence 67.6% NCT00552305 · Phase 2 · registry result, not featured evidence | 42.9%Zonisamidek NCT00848549 · Phase 3 · monotherapy show 12 more results—Zonisamide (Base Study 310, NCT004 NCT00848549 · Phase 3 · monotherapy —Zonisamide (Extension Study 314, N NCT00848549 · Phase 3 · monotherapy 27.3% NCT01140867 · Phase 4 · registry result, not featured evidence 31.7%high dose NCT01127165 · Phase 4 · registry result, not featured evidence 24.6%low dose NCT01127165 · Phase 4 · registry result, not featured evidence — NCT00855738 · Phase 4 · registry result, not featured evidence 29.2%Zonisamide (Zonisamide During Core NCT01136954 · Phase 3 · registry result, not featured evidence 33.3%Zonisamide(Placebo During Core Stu NCT01136954 · Phase 3 · registry result, not featured evidence 13.1% NCT00566254 · Phase 3 · registry result, not featured evidence 42.9% NCT00477295 · Phase 3 · registry result, not featured evidence 29.4% NCT00292461 · Phase 3 · registry result, not featured evidence 7.5%100 mg NCT00327717 · Phase 3 · registry result, not featured evidence |
| Discontinued due to AEs | 6.3%k NCT02408549 · Phase 3 · combination show 45 more results—Lacosamide (SS) Safety Follow-up P NCT02408523 · Phase 3 —Lacosamide (SS) Taper Period NCT02408523 · Phase 3 —Lacosamide (SS) Transition Period NCT02408523 · Phase 3 —Lacosamide (SS) Treatment Period NCT02408523 · Phase 3 4.8% NCT01190098 · Phase 4 · registry result, not featured evidence 9.4%First Add-on NCT00955357 · Phase 4 · registry result, not featured evidence · add on 12.8%Later Add-on NCT00955357 · Phase 4 · registry result, not featured evidence · add on 0%Lacosamide: >=2 to <4 Years NCT04627285 · Phase 3 · registry result, not featured evidence 6.9%Lacosamide: >=4 to <6 Years NCT04627285 · Phase 3 · registry result, not featured evidence 4.3% NCT01964560 · Phase 3 · registry result, not featured evidence — NCT02477839 · Phase 3 · registry result, not featured evidence — NCT02582866 · Phase 3 · registry result, not featured evidence — NCT01832038 · Phase 3 · registry result, not featured evidence 10.5% NCT02124564 · Phase 3 · registry result, not featured evidence 4.1% NCT01921205 · Phase 3 · registry result, not featured evidence 4.3%Lacosamide NCT01465997 · Phase 3 · registry result, not featured evidence —Lacosamide (SS) NCT01465997 · Phase 3 · registry result, not featured evidence — NCT01243177 · Phase 3 · registry result, not featured evidence — NCT00530855 · Phase 3 · registry result, not featured evidence — NCT02192814 · Phase 3 · registry result, not featured evidence — NCT01345058 · Phase 3 · registry result, not featured evidence · combination 15.6%400 mg/day NCT01710657 · Phase 3 · registry result, not featured evidence 4.4%200 mg/day NCT01710657 · Phase 3 · registry result, not featured evidence 6.7% NCT01484977 · Phase 3 · registry result, not featured evidence 17.6%400 mg/day NCT00520741 · Phase 3 · registry result, not featured evidence 15.1%300 mg/day NCT00520741 · Phase 3 · registry result, not featured evidence 9% NCT00515619 · Phase 3 · registry result, not featured evidence 10.3% NCT00655486 · Phase 3 · registry result, not featured evidence 11.4% NCT00522275 · Phase 3 · registry result, not featured evidence 16%400 mg NCT00655551 · Phase 3 · registry result, not featured evidence 6%300 mg NCT00655551 · Phase 3 · registry result, not featured evidence 0%200 mg NCT00655551 · Phase 3 · registry result, not featured evidence —Lacosamide Age Cohort ≥ 1 Month - NCT02710890 · Phase 2/3 · registry result, not featured evidence —Lacosamide Age Cohort ≥ 8 - < 17 Y NCT02710890 · Phase 2/3 · registry result, not featured evidence — NCT00938912 · Phase 2 · registry result, not featured evidence 0%Lacosamide 1 Month - <4 Years NCT01969851 · Phase 2 · registry result, not featured evidence 14.3%Lacosamide 12 Years - <18 Years NCT01969851 · Phase 2 · registry result, not featured evidence 0%Lacosamide 4 Years - <12 Years NCT01969851 · Phase 2 · registry result, not featured evidence —400mg NCT01458522 · Phase 2 · registry result, not featured evidence 33.3%>=1 Month to <4 Years (Safety Set) NCT00938431 · Phase 2 · registry result, not featured evidence 66.7%>=12 Years to <=17 Years (Safety S NCT00938431 · Phase 2 · registry result, not featured evidence 34.8%>=4 Years to <12 Years (Safety Set NCT00938431 · Phase 2 · registry result, not featured evidence 5.1% NCT01118962 · Phase 2 · registry result, not featured evidence 10.2% NCT01118949 · Phase 2 · registry result, not featured evidence 13% NCT00552305 · Phase 2 · registry result, not featured evidence | 11%Zonisamidek NCT00848549 · Phase 3 · monotherapy show 12 more results—Zonisamide (Base Study 310, NCT004 NCT00848549 · Phase 3 · monotherapy —Zonisamide (Extension Study 314, N NCT00848549 · Phase 3 · monotherapy 18.2% NCT01140867 · Phase 4 · registry result, not featured evidence 3.3%high dose NCT01127165 · Phase 4 · registry result, not featured evidence 3.1%low dose NCT01127165 · Phase 4 · registry result, not featured evidence — NCT00855738 · Phase 4 · registry result, not featured evidence 2.8%Zonisamide (Zonisamide During Core NCT01136954 · Phase 3 · registry result, not featured evidence 4.2%Zonisamide(Placebo During Core Stu NCT01136954 · Phase 3 · registry result, not featured evidence 0.9% NCT00566254 · Phase 3 · registry result, not featured evidence 11% NCT00477295 · Phase 3 · registry result, not featured evidence 11.8% NCT00292461 · Phase 3 · registry result, not featured evidence 5%100 mg NCT00327717 · Phase 3 · registry result, not featured evidence |
| Serious AEs | 22.6%k NCT02408549 · Phase 3 · combination show 45 more results9.1%Lacosamide (SS) Safety Follow-up P NCT02408523 · Phase 3 0%Lacosamide (SS) Taper Period NCT02408523 · Phase 3 3%Lacosamide (SS) Transition Period NCT02408523 · Phase 3 6.6%Lacosamide (SS) Treatment Period NCT02408523 · Phase 3 7.1% NCT01190098 · Phase 4 · registry result, not featured evidence 8.3%First Add-on NCT00955357 · Phase 4 · registry result, not featured evidence · add on 5.3%Later Add-on NCT00955357 · Phase 4 · registry result, not featured evidence · add on 10.5%Lacosamide: >=2 to <4 Years NCT04627285 · Phase 3 · registry result, not featured evidence 17.2%Lacosamide: >=4 to <6 Years NCT04627285 · Phase 3 · registry result, not featured evidence 20.6% NCT01964560 · Phase 3 · registry result, not featured evidence 4.7% NCT02477839 · Phase 3 · registry result, not featured evidence 14.2% NCT02582866 · Phase 3 · registry result, not featured evidence 17.5% NCT01832038 · Phase 3 · registry result, not featured evidence 10.5% NCT02124564 · Phase 3 · registry result, not featured evidence 6.4% NCT01921205 · Phase 3 · registry result, not featured evidence —Lacosamide NCT01465997 · Phase 3 · registry result, not featured evidence 11.5%Lacosamide (SS) NCT01465997 · Phase 3 · registry result, not featured evidence 8.1% NCT01243177 · Phase 3 · registry result, not featured evidence 17.4% NCT00530855 · Phase 3 · registry result, not featured evidence 0% NCT02192814 · Phase 3 · registry result, not featured evidence 0% NCT01345058 · Phase 3 · registry result, not featured evidence · combination 5%400 mg/day NCT01710657 · Phase 3 · registry result, not featured evidence 1.1%200 mg/day NCT01710657 · Phase 3 · registry result, not featured evidence 6.7% NCT01484977 · Phase 3 · registry result, not featured evidence 6.6%400 mg/day NCT00520741 · Phase 3 · registry result, not featured evidence 3.8%300 mg/day NCT00520741 · Phase 3 · registry result, not featured evidence 23.1% NCT00515619 · Phase 3 · registry result, not featured evidence 10.3% NCT00655486 · Phase 3 · registry result, not featured evidence 23.1% NCT00522275 · Phase 3 · registry result, not featured evidence 4%400 mg NCT00655551 · Phase 3 · registry result, not featured evidence 0%300 mg NCT00655551 · Phase 3 · registry result, not featured evidence 0%200 mg NCT00655551 · Phase 3 · registry result, not featured evidence 0%Lacosamide Age Cohort ≥ 1 Month - NCT02710890 · Phase 2/3 · registry result, not featured evidence 0%Lacosamide Age Cohort ≥ 8 - < 17 Y NCT02710890 · Phase 2/3 · registry result, not featured evidence 22.5% NCT00938912 · Phase 2 · registry result, not featured evidence 0%Lacosamide 1 Month - <4 Years NCT01969851 · Phase 2 · registry result, not featured evidence 4.8%Lacosamide 12 Years - <18 Years NCT01969851 · Phase 2 · registry result, not featured evidence 0%Lacosamide 4 Years - <12 Years NCT01969851 · Phase 2 · registry result, not featured evidence 22.2%400mg NCT01458522 · Phase 2 · registry result, not featured evidence 20%>=1 Month to <4 Years (Safety Set) NCT00938431 · Phase 2 · registry result, not featured evidence 0%>=12 Years to <=17 Years (Safety S NCT00938431 · Phase 2 · registry result, not featured evidence 13%>=4 Years to <12 Years (Safety Set NCT00938431 · Phase 2 · registry result, not featured evidence 7.7% NCT01118962 · Phase 2 · registry result, not featured evidence 2% NCT01118949 · Phase 2 · registry result, not featured evidence 33.8% NCT00552305 · Phase 2 · registry result, not featured evidence | —Zonisamidek NCT00848549 · Phase 3 · monotherapy show 12 more results5.3%Zonisamide (Base Study 310, NCT004 NCT00848549 · Phase 3 · monotherapy 5.1%Zonisamide (Extension Study 314, N NCT00848549 · Phase 3 · monotherapy 1.7% NCT01140867 · Phase 4 · registry result, not featured evidence 1.7%high dose NCT01127165 · Phase 4 · registry result, not featured evidence 3.1%low dose NCT01127165 · Phase 4 · registry result, not featured evidence 0% NCT00855738 · Phase 4 · registry result, not featured evidence 9.7%Zonisamide (Zonisamide During Core NCT01136954 · Phase 3 · registry result, not featured evidence 4.2%Zonisamide(Placebo During Core Stu NCT01136954 · Phase 3 · registry result, not featured evidence 3.7% NCT00566254 · Phase 3 · registry result, not featured evidence 5.3% NCT00477295 · Phase 3 · registry result, not featured evidence 0% NCT00292461 · Phase 3 · registry result, not featured evidence 0%100 mg NCT00327717 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | show 44 more resultsdrooling 11.1% (placebo 0%) grand mal convulsion 11.1% (placebo 0%) laceration 11.1% (placebo 0%) NCT02408523 · Phase 3 dizziness 3% (placebo 0%) nasopharyngitis 1% (placebo 0%) vertigo 1% (placebo 0%) NCT02408523 · Phase 3 dizziness 21.5% (placebo 0%) somnolence 14.9% (placebo 0%) headache 13.2% (placebo 0%) NCT02408523 · Phase 3 dizziness 42.9% (placebo 30%) headache 40.5% (placebo 40%) common cold/flu 21.4% (placebo 10%) NCT01190098 · Phase 4 · registry result, not featured evidence dizziness 31.3% headache 13.5% vertigo 9.4% NCT00955357 · Phase 4 · registry result, not featured evidence · add on dizziness 33.1% somnolence 15% headache 11.4% NCT00955357 · Phase 4 · registry result, not featured evidence · add on upper respiratory tract infection 26.3% NCT04627285 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 13.8% NCT04627285 · Phase 3 · registry result, not featured evidence pyrexia 15.9% upper respiratory tract infection 15.4% nasopharyngitis 10.6% NCT01964560 · Phase 3 · registry result, not featured evidence somnolence 14.1% (placebo 3.9%) irritability 5.5% (placebo 4.7%) pyrexia 5.5% (placebo 11.8%) NCT02477839 · Phase 3 · registry result, not featured evidence nasopharyngitis 33% dizziness 26.4% upper respiratory tract infection 20.9% NCT01832038 · Phase 3 · registry result, not featured evidence dizziness 52.6% somnolence 42.1% nasopharyngitis 36.8% NCT02124564 · Phase 3 · registry result, not featured evidence somnolence 16.4% (placebo 6.4%) nasopharyngitis 11.7% (placebo 5.8%) dizziness 10.5% (placebo 7.6%) NCT01921205 · Phase 3 · registry result, not featured evidence nasopharyngitis 7.2% headache 6.1% dizziness 4.3% NCT01465997 · Phase 3 · registry result, not featured evidence headache 13.5% dizziness 11.9% fatigue 7.7% NCT01243177 · Phase 3 · registry result, not featured evidence dizziness 27.6% headache 17.1% nausea 14.3% NCT00530855 · Phase 3 · registry result, not featured evidence abdominal pain upper 11.1% injection site erythema 11.1% injection site pain 11.1% NCT02192814 · Phase 3 · registry result, not featured evidence erectile dysfunction 11.1% fatigue 11.1% memory/cognitive difficulties/confusion 11.1% NCT01345058 · Phase 3 · registry result, not featured evidence · combination 400 mg/day dizziness 35% (placebo 13%) nasopharyngitis 16.1% (placebo 13%) headache 10.6% (placebo 6%) NCT01710657 · Phase 3 · registry result, not featured evidence 200 mg/day dizziness 18% (placebo 13%) nasopharyngitis 15.3% (placebo 13%) somnolence 9.8% (placebo 4.9%) NCT01710657 · Phase 3 · registry result, not featured evidence dizziness 23.3% headache 15% fatigue 8.3% NCT01484977 · Phase 3 · registry result, not featured evidence 400 mg/day dizziness 27% nausea 14.4% headache 14.1% NCT00520741 · Phase 3 · registry result, not featured evidence 300 mg/day headache 19.8% dizziness 17.9% convulsion 16% NCT00520741 · Phase 3 · registry result, not featured evidence dizziness 24.2% headache 14.4% nasopharyngitis 13.8% NCT00515619 · Phase 3 · registry result, not featured evidence dizziness 44.3% diplopia 17.5% vomiting 16.5% NCT00655486 · Phase 3 · registry result, not featured evidence dizziness 50% headache 21.8% contusion 18.5% NCT00522275 · Phase 3 · registry result, not featured evidence 400 mg dizziness 60% somnolence 36% nausea 24% NCT00655551 · Phase 3 · registry result, not featured evidence 300 mg dizziness 46% somnolence 34% fatigue 18% NCT00655551 · Phase 3 · registry result, not featured evidence 200 mg dizziness 20% gait disturbance 8% headache 8% NCT00655551 · Phase 3 · registry result, not featured evidence functional gastrointestinal disorder 2.1% pyrexia 2.1% respiratory tract infection 2.1% NCT02710890 · Phase 2/3 · registry result, not featured evidence blood triglycerides increased 3.6% blood cholesterol increased 1.8% functional gastrointestinal disorder 0% NCT02710890 · Phase 2/3 · registry result, not featured evidence nasopharyngitis 24.9% upper respiratory tract infection 23.6% pyrexia 21.9% NCT00938912 · Phase 2 · registry result, not featured evidence nasopharyngitis 50% pyrexia 40% somnolence 40% NCT01969851 · Phase 2 · registry result, not featured evidence headache 19% nasopharyngitis 14.3% pharyngotonsillitis 14.3% NCT01969851 · Phase 2 · registry result, not featured evidence pyrexia 25% cough 16.7% upper respiratory tract infection 16.7% NCT01969851 · Phase 2 · registry result, not featured evidence 400mg respiratory failure 6.7% acute respiratory failure 4.4% bradycardia 4.4% NCT01458522 · Phase 2 · registry result, not featured evidence irritability 20% pharyngotonsillitis 20% diarrhoea 13.3% NCT00938431 · Phase 2 · registry result, not featured evidence balance disorder 22.2% dizziness 22.2% rash 22.2% NCT00938431 · Phase 2 · registry result, not featured evidence vomiting 30.4% diarrhoea 17.4% dizziness 13% NCT00938431 · Phase 2 · registry result, not featured evidence dizziness 25.6% upper respiratory tract infection 25.6% headache 17.9% NCT01118962 · Phase 2 · registry result, not featured evidence dizziness 38.8% nausea 26.5% headache 16.3% NCT01118949 · Phase 2 · registry result, not featured evidence dizziness 39.7% headache 20.8% nausea 17.3% NCT00552305 · Phase 2 · registry result, not featured evidence | show 11 more resultsdizziness 28.1% somnolence 24% anorexia 18.2% NCT01140867 · Phase 4 · registry result, not featured evidence high dose dizziness 5% micturition disorder 5% somnolence 5% NCT01127165 · Phase 4 · registry result, not featured evidence low dose anorexia 4.6% fatigue 3.1% somnolence 3.1% NCT01127165 · Phase 4 · registry result, not featured evidence somnolence 7.5% weight increased 5% dizziness 2.5% NCT00855738 · Phase 4 · registry result, not featured evidence nasopharyngitis 12.5% headache 9.7% weight decreased 8.3% NCT01136954 · Phase 3 · registry result, not featured evidence nasopharyngitis 8.3% weight decreased 8.3% decreased appetite 6.9% NCT01136954 · Phase 3 · registry result, not featured evidence decreased appetite 6.5% (placebo 4%) headache 6.5% (placebo 7%) nasopharyngitis 5.6% (placebo 9%) NCT00566254 · Phase 3 · registry result, not featured evidence headache 10.3% decreased appetite 7.8% weight decreased 6.8% NCT00477295 · Phase 3 · registry result, not featured evidence hepatic enzyme abnormal 8.8% blood alkaline phosphatase increased 5.9% dizziness 5.9% NCT00292461 · Phase 3 · registry result, not featured evidence 100 mg anorexia 18.3% (placebo 5.1%) somnolence 12.5% (placebo 14.4%) headache 10.8% (placebo 5.1%) NCT00327717 · Phase 3 · registry result, not featured evidence |
Notes
- aTrial phases differ: Phase 3 versus Phase 4.
- bPopulation context differs: registered conditions differ.
- cTreatment context has not been resolved for both arms.
- dAssessment timepoints differ: 323 weeks versus 16 weeks.
- eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- fPopulation comparability has not been reviewed for both studies.
- gAssessment timepoints differ: 24 weeks versus 20 weeks.
- hAssessment timepoints differ: 26 weeks versus 12 weeks.
- iTrial phases differ: Phase 2 versus Phase 4.
- jThe assessment timepoint is not available for both results.
- kPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Lacosamide
show 1 more result
show 3 more results
+ 19 further endpoints in the CSV export.
Zonisamide (Zonegran)
show 4 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
+ 9 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Lacosamide's landscape · Zonisamide (Zonegran)'s landscape